Summarized by Masters of Longevity from Singularity Hub.
A Stanford team simulated a virtual biotech made of up to 37,000 AI agents that analyze trial data, prioritize targets, and design therapeutic strategies across the drug development pipeline.
Key Takeaways
- Agents reviewed outcomes from 37,075 Phase II and III trials by extracting results from registries and publications.
- Drugs targeting switch-like genes in specific cell types were 48% more likely to reach market and had 32% fewer adverse events.
- The system independently proposed a B7-H3 targeted therapy strategy later mirrored by a pharmaceutical developer's breakthrough-designated therapy.
